Skip to content
Peptigraph home
Shop Peptides50% off*

How Survodutide Works: Mechanism and Pharmacology

How Survodutide works: its target and mechanism as the sources state them, how long it acts, and what is still unknown.

Medical review pendingGLP-1 / glucagon dual agonistUpdated
Class
GLP-1 / glucagon dual agonist
FDA status
Not approved
Investigational · phase 3
Routes studied
subcutaneous
Half-life
[pending]
by route, with source

How long it acts

No published half-life found for Survodutide (PubMed search, 2 Oct 2026)

Two receptors, one peptide

The SYNCHRONIZE-MASLD report calls survodutide a glucagon receptor and GLP-1 receptor dual agonist under investigation for obesity and related diseases.[5]

The MASH trial authors reasoned that dual agonism might outperform GLP-1 receptor agonism alone in MASH.[6]

What dual agonism looked like in people

Pooled across trials, survodutide lowered fasting glucagon by 7 pmol/L as well as HbA1c.[7]

In people with cirrhosis, liver fat content, liver stiffness and body weight were generally reduced after 28 weeks.[8]

In the MASLD phase 3 trial, 84.2% of survodutide recipients reached a liver-fat fall of 30% or more, against 24.3% on placebo (efficacy estimand).[5]

Weekly injections and slow escalation

The obesity phase 2 trial gave weekly injections with 20 weeks of dose escalation, then 26 weeks of dose maintenance.[9]

The diabetes phase 2 authors said the gut side effects could be eased with slower dose escalation.[10]

The pharmacokinetic study in cirrhosis found similar exposure (AUC and Cmax) to healthy people after a single dose.[8]

What the cached papers do not give

A 2 Oct 2026 PubMed search for survodutide with half-life or pharmacokinetic terms returned 3 papers, and the cirrhosis phase 1 abstract reports exposure ratios but no half-life figure, so how long one dose acts is not stated in the cached abstracts.

Calculated from query (survodutide[tiab] OR BI456906[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]); date 2026-10-02; count 3. Formula: count taken from the evidence file's search record

Common questions

How long does Survodutide act in the body?

We found no published half-life for Survodutide (PubMed search, 2 Oct 2026), so how long it acts is unknown.

What is the survodutide mechanism of action?

It acts as a dual agonist at the glucagon receptor and the GLP-1 receptor.[5]

More on Survodutide

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.BenefitsClaimed benefits next to what published studies measured.

Sources

  1. 1PubMed search: survodutide[tiab] OR BI456906[tiab] (86 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (56 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  3. 3PubMed search: (survodutide[tiab] OR BI456906[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026PMID 42252333Accessed 2 Oct 2026
  6. 6A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026
  7. 7Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2025PMID 40922121Accessed 2 Oct 2026
  8. 8Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.Journal of hepatology · 2024PMID 38857788Accessed 2 Oct 2026
  9. 9Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology · 2024PMID 38330987Accessed 2 Oct 2026
  10. 10Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia · 2024PMID 38095657Accessed 2 Oct 2026

Found an error? Report a correction.